Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 3/20 | 0.49 |
| ▸ | SRC | P12931 | 12/20 | 0.43 |
| ▸ | ABL1 | P00519 | 11/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.43 |
| ▸ | YES1 | P07947 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612713 | 0.84 | TTK (0.67) | TTKSRCABL1JAK2JAK3 | |
| SCHEMBL612697 | 0.82 | SRC (0.56) | TTKSRCABL1PDGFRBJAK2 | |
| SCHEMBL613379 | 0.78 | LRRK2 (0.47) | TTKSRCABL1PDGFRBYES1 | |
| SCHEMBL41292 | 0.76 | LRRK2 (0.49) | TTKSRCABL1PDGFRBJAK2 | |
| SCHEMBL41597 | 0.76 | LRRK2 (0.47) | TTKSRCABL1PDGFRBYES1 | |
| SCHEMBL614357 | 0.75 | SYK (0.43) | TTKSRCABL1PDGFRBYES1 | |
| SCHEMBL612670 | 0.75 | SRC (0.45) | TTKSRCABL1PDGFRBEPHB4 | |
| SCHEMBL615235 | 0.75 | ABL1 (0.51) | SRCABL1PDGFRBYES1KDR | |
| SCHEMBL612376 | 0.75 | SRC (0.46) | TTKSRCABL1PDGFRBYES1 | |
| SCHEMBL41596 | 0.74 | LRRK2 (0.43) | TTKSRCABL1PDGFRBYES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041195-A1 | Heterocyclic compounds | FOVEA PHARMACEUTICALS | 2012-02-16 | — | — | US | claimed |
| US-20120041195-A1 | Heterocyclic compounds | FOVEA PHARMACEUTICALS | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041195-A1 | Heterocyclic compounds | MAP3K1, MAP3K5, MAP3K2 | TTK 277/4885SRC 1204/4885ABL1 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.